Appears Keizo Koya VP of Drug Development is departing based on the 8k filed this morning. I wonder if his departure and the recent additions of Dvorit Samid (Medical Affairs) and George Farmer (Corporate Development) is a signal that Ganetespib trial success is approaching. They seem to be reordering their staffing for drug registration. I believe Koya was responsible for Elesclomol, and Synta's focus is now Ganetespib.
tech....went through the same discussion with a very similar situation at genvec. Many had the same thoughts/arguments as you....but it turned out NOT to be the case. It got pretty ugly...so be careful with that argument. I'm not saying you are wrong...but I've been down this road before and you MAY be wrong. I will continue to follow..... barney
Probably, but a little humility would serve you well. There is no such thing as a slam dunk when it comes to cancer treatments. Remember, Safi was gloating at the JPM conference just weeks before elesclomol blew up.